LINC00632 and breast cancer: It was suggested that silencing CDR1as in vivo could increase the sensitivity of drug‐resistant transplanted tumours to cisplatin in breast cancer, while inhibition of miR‐7 expression could reverse the effect of silencing CDR1as on the sensitivity of drug‐resistant transplanted tumours to cisplatin in breast cancer.